このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Personalized Meal Timing and Walking Based on Glucose Patterns in Adults With Prediabetes (CLOCK-PRIME)

2026年5月24日 更新者:Saima Abass Tahammal、Shifa International Hospital

CGM-Phenotyped Circadian Glycemic Vulnerability Windows to Personalize Meal Timing and Postprandial Activity in Prediabetes : A Randomized Controlled Trial

This study will test whether glucose sensor data can be used to identify the time of day when adults with prediabetes are most likely to have high blood sugar after meals. Participants will first wear a continuous glucose monitor and wrist activity monitor and record meal times for 10 days. These data will be used to classify each participant's personal "glycemic vulnerability window," such as morning, evening, or generally variable patterns.

Participants will then be randomly assigned to either personalized meal timing plus a short walk after their most vulnerable meal, or to an attention-matched control group receiving sleep hygiene and general step-count advice. The main outcome will be the change in post-meal glucose exposure during each participant's vulnerable window after 4 weeks.

調査の概要

詳細な説明

Prediabetes is a high-risk metabolic state in which postprandial glucose excursions and glycemic variability may contribute to progression toward type 2 diabetes. Although lifestyle modification can reduce diabetes risk, conventional advice is usually generic and does not account for individual differences in the timing of glucose intolerance across the day. Emerging evidence suggests that circadian biology, meal timing, sleep timing, and postprandial activity may influence glucose regulation, but it remains unclear whether continuous glucose monitoring can be used to personalize the timing of meals and brief activity in adults with prediabetes.

CLOCK-PRIME is a single-center, two-arm, randomized controlled trial in adults with prediabetes. Participants will undergo a 10-day blinded observational run-in period using continuous glucose monitoring, wrist actigraphy, and timestamped meal-photo logging. Run-in data will be used to classify participants into pre-specified circadian glycemic phenotypes based on postprandial glucose incremental area under the curve during morning and evening windows. Participants will be categorized as morning-vulnerable, evening-vulnerable, or globally variable.

After phenotype classification, participants will be randomized to either a phenotype-guided intervention or an attention-matched active control group. The intervention group will receive personalized guidance to shift the highest glycemic-load meal away from the participant's highest-vulnerability window and toward the lowest-vulnerability window. Participants will also be advised to perform a 10-minute brisk walk within 30 minutes after the meal occurring in their highest-vulnerability window. The control group will receive standardized sleep hygiene advice and a general step-count goal, without meal-timing or postprandial walking instructions.

The primary endpoint is the change from baseline to week 4 in vulnerable-window postprandial glucose incremental area under the curve measured by continuous glucose monitoring. Secondary endpoints include time in range, time above range, glucose coefficient of variation, mean postprandial peak glucose, nocturnal mean glucose, sleep regularity, social jetlag, and actigraphy-derived activity patterns. Exploratory mechanistic outcomes include fasting dried-blood-spot measures of cortisol:insulin ratio and selected primary bile acids to assess whether changes in neuroendocrine or enterohepatic metabolic pathways accompany improvement in glycemic vulnerability.

The study is designed to determine whether CGM-derived circadian glycemic vulnerability windows can support a feasible precision lifestyle strategy for reducing postprandial glycemic burden in adults with prediabetes.

研究の種類

介入

入学 (推定)

105

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Shaikhupura
      • Lahore、Shaikhupura、パキスタン、50
        • 募集
        • Shifa International Hospital
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Age 30 to 70 years
  • Prediabetes, defined as either:
  • HbA1c 5.7% to 6.4% within 3 months of screening, or
  • Fasting plasma glucose 100 to 125 mg/dL on two separate occasions
  • Body mass index 23 to 40 kg/m²
  • Owns a smartphone compatible with study applications
  • Willing to wear a continuous glucose monitor and wrist activity monitor during the study period
  • Willing to record meals using timestamped meal-photo logging
  • Able to provide written informed consent

Exclusion Criteria:

  • Current or prior diagnosis of type 1 diabetes or type 2 diabetes
  • Use of glucose-lowering medication within the past 3 months
  • Use of systemic corticosteroid medication within the past 3 months
  • Use of prescription weight-loss medication within the past 3 months
  • Current shift work
  • Transmeridian travel across more than 2 time zones within 4 weeks before enrollment
  • Known untreated or unstable sleep disorder, including obstructive sleep apnea, narcolepsy, or insomnia disorder
  • Pregnancy, planned pregnancy, or breastfeeding
  • Gastrointestinal disease or surgery likely to affect nutrient absorption
  • Current participation in a structured dietary or exercise intervention program
  • Estimated glomerular filtration rate less than 60 mL/min/1.73 m²
  • Inability or unwillingness to comply with continuous glucose monitoring, wrist actigraphy, meal logging, or study visits

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:Phenotype-Guided Meal Timing and Postprandial Walking
Participants will receive personalized lifestyle guidance based on their CGM-derived circadian glycemic vulnerability phenotype. They will be advised to shift their highest glycemic-load meal away from their highest-vulnerability window and toward their lowest-vulnerability window, and to perform a 10-minute brisk walk within 30 minutes after the meal occurring in their highest-vulnerability window.
Participants randomized to this arm will receive personalized lifestyle guidance based on their CGM-derived circadian glycemic vulnerability phenotype. During the 10-day run-in period, continuous glucose monitoring, wrist actigraphy, and timestamped meal-photo logs will be used to identify the time window in which each participant has the greatest postprandial glucose exposure. Participants will be advised to shift their highest glycemic-load meal away from their highest-vulnerability window and toward their lowest-vulnerability window where feasible. They will also be instructed to perform a 10-minute brisk walk within 30 minutes after the meal occurring in their highest-vulnerability window on at least 5 days per week. The intervention will be delivered through structured dietitian counseling sessions and brief weekly check-in calls. No calorie restriction, prescribed macronutrient diet, or weight-loss target will be imposed.
他の名前:
  • Phenotype-Guided Meal Timing
  • Postprandial Walking
アクティブコンパレータ:Attention-Matched Sleep Hygiene and Step-Count Advice
Participants will receive standardized sleep hygiene advice and general step-count guidance matched for contact time with the intervention group. They will not receive meal-timing advice, carbohydrate-timing advice, or postprandial walking instructions.
Participants randomized to the active comparator arm will receive standardized sleep hygiene and general physical activity guidance matched for contact time with the intervention arm. Sleep hygiene advice will include maintaining regular sleep and wake times, aiming for adequate sleep duration, and reducing screen exposure before bedtime. Participants will also be advised to increase their average daily step count by approximately 10% above their run-in baseline, with steps distributed freely throughout the day. This arm will not include any advice on meal timing, carbohydrate timing, glycemic vulnerability windows, or postprandial walking. The intervention will be delivered through structured dietitian counseling sessions and brief weekly check-in calls.
他の名前:
  • 睡眠衛生
  • Step-Count Advice

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Vulnerable-Window Postprandial Glucose Incremental Area Under the Curve
時間枠:Baseline run-in period to Week 4, unit of measure: mg/dL·min
Change from baseline run-in period to week 4 in mean postprandial glucose incremental area under the curve during each participant's pre-specified highest glycemic vulnerability window. Postprandial glucose incremental area under the curve will be calculated from continuous glucose monitoring data over 120 minutes after logged meals using the trapezoidal rule.
Baseline run-in period to Week 4, unit of measure: mg/dL·min

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年6月1日

一次修了 (推定)

2026年6月30日

研究の完了 (推定)

2026年7月15日

試験登録日

最初に提出

2026年5月24日

QC基準を満たした最初の提出物

2026年5月24日

最初の投稿 (実際)

2026年6月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月1日

QC基準を満たした最後の更新が送信されました

2026年5月24日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

De-identified individual participant data underlying the published results may be shared upon reasonable request after publication, subject to institutional approval, data-use agreement, and protection of participant confidentiality.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する